Home > Riviste > Giornale Italiano di Dermatologia e Venereologia > Fascicoli precedenti > Giornale Italiano di Dermatologia e Venereologia 2015 August;150(4) > Giornale Italiano di Dermatologia e Venereologia 2015 August;150(4):351-5

ULTIMO FASCICOLO
 

ARTICLE TOOLS

Estratti
Per citare questo articolo

GIORNALE ITALIANO DI DERMATOLOGIA E VENEREOLOGIA

Rivista di Dermatologia e Malattie Sessualmente Trasmesse


Official Journal of the Italian Society of Dermatology and Sexually Transmitted Diseases
Indexed/Abstracted in: EMBASE, PubMed/MEDLINE, Science Citation Index Expanded (SciSearch), Scopus
Impact Factor 1,311


eTOC

 

ORIGINAL ARTICLES  


Giornale Italiano di Dermatologia e Venereologia 2015 August;150(4):351-5

Copyright © 2015 EDIZIONI MINERVA MEDICA

lingua: Inglese

Comparison of the efficacy and safety of zinc sulfate vs. placebo in the treatment of pruritus of hemodialytic patients: a pilot randomized, triple-blind study

Mapar M. A. 1, Pazyar N. 1, Siahpoosh A. 2, Latifi S. M. 3, Beladi Mousavi S. S. 4, Khazanee A. 5

1 Dermatology, Department of Dermatology, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran; 2 Pharmacognesy, Faculty of Pharmacology, Medical Plants and Natural Products Research, Ahvaz, Iran; 3 Department of Biostatics, Faculty of Health, Member of Ahvaz Diabetics Research Center, Ahvaz, Iran; 4 Internal Medicine, Department of Internal Medicine, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran; 5 Dermatologist, Department of Dermatology, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran


PDF  


AIM: Improvement of uremic pruritus has been reported under short-term administration of oral zinc sulfate. Objective of the study was to confirm efficacy and safety of oral zinc sulfate in pruritus of hemodialytic patients
METHODS: A pilot randomized, triple-blind study was conducted to evaluate the pruritus of hemodialytic patients. Forty eligible patients were screened and assigned to receive either zinc sulfate (220 mg/d) or matched placebo for a 4-week trial. Pruritus scale was evaluated at the initiation of the study and 1, 2, 3, and 4 weeks after the treatment. We used a modified score proposed by Duo assessing pruritus severity, distribution of pruritus, and frequency of pruritus-related sleep disturbance.
RESULTS: Thirty-six patients completed the study. The mean pruritus score decreased in both groups during the first and the second weeks of trial; however, it was more prominent in zinc group than placebo one. In the zinc group, 4 (20%) patients showed pruritus discontinuation during treatment period whereas, in the placebo group, the number was only 1 (5%) patient. Nonetheless, T-test revealed no statistically significant difference between the zinc and placebo groups (P=0.88 and P=0.56, respectively).
CONCLUSION: Our findings demonstrated that oral zinc sulfate (220 mg/d) during four weeks treatment might be safe and effective in discontinuation of uremic pruritus, but it was not significant. This could be because of the small number of patients; therefore, we suggest conducting more studies with larger sample size.

inizio pagina

Publication History

Per citare questo articolo

Mapar MA, Pazyar N, Siahpoosh A, Latifi SM, Beladi Mousavi SS, Khazanee A. Comparison of the efficacy and safety of zinc sulfate vs. placebo in the treatment of pruritus of hemodialytic patients: a pilot randomized, triple-blind study. G Ital Dermatol Venereol 2015 August;150(4):351-5. 

Corresponding author e-mail

dr.pazyar@gmail.com